{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-09T19:29:19.051305+00:00","company":{"ticker":"LQDA","cik":1819576,"company_name":"Liquidia Corp"},"pagination":{"limit":100,"returned":9,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"BofA Securities, Inc.","detail":"underwriting","count":1,"first_seen":"2023-12-12T23:59:59+00:00","last_seen":"2023-12-12T23:59:59+00:00","evidence_fact_ids":[88893]},{"display_name":"HealthCare Royalty Partners IV, L.P.","detail":"credit_facility","count":1,"first_seen":"2024-01-05T23:59:59+00:00","last_seen":"2024-01-05T23:59:59+00:00","evidence_fact_ids":[83176]},{"display_name":"Legend Aggregator, LP","detail":"equity_purchase","count":1,"first_seen":"2024-01-05T23:59:59+00:00","last_seen":"2024-01-05T23:59:59+00:00","evidence_fact_ids":[83177]},{"display_name":"Roger Jeffs","detail":"equity_purchase","count":1,"first_seen":"2023-12-12T23:59:59+00:00","last_seen":"2023-12-12T23:59:59+00:00","evidence_fact_ids":[88894]}]},"facts":[{"fact_type":"earnings_release","fact_key":"a4c06057126af08b2a14bfac77459390e7a1bfdc","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2026-05-11T23:59:59+00:00","payload":{"eps_text":"$0.60 per basic and $0.52 per diluted share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$52.9 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-11","result_type":"reported_results","revenue_text":"$129.9 million"},"claim":"Liquidia Corp reported first quarter ended March 31, 2026 results: revenue $129.9 million, net income $52.9 million, EPS $0.60 per basic and $0.52 per diluted share.","evidence_excerpt":"First Quarter 2026 Financial Results YUTREPIA sales led to the company’s third consecutive quarter of profitability with net income of $52.9 million and positive non-GAAP adjusted EBITDA of $71.2 million in the first quarter of 2026. Cash and cash equivalents totaled $222.8 million as of March 31, 2026, compared to $190.7 million as of December 31, 2025. Product sales, net, were $129.9 million for the three months ended March 31, 2026.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001104659-26-058234","anchor_url":"https://secwatch.observer/filing/0001104659-26-058234#claim-a4c06057126af08b2a14bfac77459390e7a1bfdc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465926058234/0001104659-26-058234-index.htm"},{"fact_type":"earnings_release","fact_key":"a01f1a365dd70a32b27d2b43a43e41c82e123248","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2024-03-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full year ended December 31, 2023","report_date":"2024-03-13","result_type":"reported_results","revenue_text":"$17.5 million"},"claim":"Liquidia Corp reported full year ended December 31, 2023 results: revenue $17.5 million.","evidence_excerpt":"$25.0 million. HCRx has now invested $67.5 million\nin non-dilutive capital from the $100 million originally contemplated from four tranches under the RIFA. Revenue was $17.5 million for the year ended December 31, 2023, compared with $15.9 million for the\nyear ended December 31, 2022. Revenue related primarily to the sale of Treprostinil Injection under the","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-033684","anchor_url":"https://secwatch.observer/filing/0001104659-24-033684#claim-a01f1a365dd70a32b27d2b43a43e41c82e123248","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924033684/0001104659-24-033684-index.htm"},{"fact_type":"executive_change","fact_key":"d474d76ac6","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"promoted","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-01-15","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Michael Kaseta changed role as Chief Operating Officer at Liquidia Corp.","evidence_excerpt":"On January 15, 2024 (the “Effective Date”), the Company promoted Michael Kaseta, the current Chief Financial Officer (“CFO”) of the Company, to the role of Chief Operating Officer (the “COO”), effective immediately.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-005009","anchor_url":"https://secwatch.observer/filing/0001104659-24-005009#claim-d474d76ac6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924005009/0001104659-24-005009-index.htm"},{"fact_type":"executive_change","fact_key":"f96e3e4976","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2024-01-19T23:59:59+00:00","payload":{"action":"terminated","action_category":"departure","departure_tone":"termination","effective_date":"2024-01-15","interim":false,"role":"Chief Operations Officer","role_category":"coo","successor_name":"Michael Kaseta","successor_named":true},"claim":"Robert Lippe was terminated as Chief Operations Officer at Liquidia Corp.","evidence_excerpt":"On January 15, 2024, Liquidia Corporation, a Delaware corporation (the “Company”) terminated Robert Lippe from his position as the Chief Operations Officer of the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-005009","anchor_url":"https://secwatch.observer/filing/0001104659-24-005009#claim-f96e3e4976","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924005009/0001104659-24-005009-index.htm"},{"fact_type":"material_agreement","fact_key":"48f942284ab92fe233dc97241ec60e83e51207ad","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Registration Rights Agreement","agreement_type":"equity_purchase","counterparty":"Legend Aggregator, LP","effective_date":"2024-01-04","item_codes_triggered":["1.01"],"value_text":"Agreement to file registration statement for resale of Private Placement Shares"},"claim":"Liquidia Corp entered into Registration Rights Agreement with Legend Aggregator, LP valued at Agreement to file registration statement for resale of Private Placement Shares (effective 2024-01-04).","evidence_excerpt":"In connection with the Private Placement, on January 4, 2024, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-001504","anchor_url":"https://secwatch.observer/filing/0001104659-24-001504#claim-48f942284ab92fe233dc97241ec60e83e51207ad","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924001504/0001104659-24-001504-index.htm"},{"fact_type":"material_agreement","fact_key":"c45ce608bc3ee6ca7daea66ddde67d52c72282ef","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2024-01-05T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Fourth Amendment to Revenue Interest Financing Agreement","agreement_type":"credit_facility","counterparty":"HealthCare Royalty Partners IV, L.P.","effective_date":"2024-01-03","item_codes_triggered":["1.01"],"value_text":"$25,000,000 additional funding"},"claim":"Liquidia Corp entered into Fourth Amendment to Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. valued at $25,000,000 additional funding (effective 2024-01-03).","evidence_excerpt":"On January 3, 2024, Liquidia Technologies and HCR entered into a Fourth Amendment to the Financing Agreement (the “Fourth Amendment”) to fund an additional $25.0 million thereunder.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-001504","anchor_url":"https://secwatch.observer/filing/0001104659-24-001504#claim-c45ce608bc3ee6ca7daea66ddde67d52c72282ef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465924001504/0001104659-24-001504-index.htm"},{"fact_type":"material_agreement","fact_key":"ab4b7e78f905ffd575ac9e83a3c29cd433d9e24e","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2023-12-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Common Stock Purchase Agreement","agreement_type":"equity_purchase","counterparty":"Roger Jeffs","effective_date":"2023-12-12","item_codes_triggered":["1.01"],"value_text":"Private sale of 139,665 unregistered shares of common stock at $7.16 per share, aggregate investment"},"claim":"Liquidia Corp entered into Common Stock Purchase Agreement with Roger Jeffs valued at Private sale of 139,665 unregistered shares of common stock at $7.16 per share, aggregate investment (effective 2023-12-12).","evidence_excerpt":"Concurrently with the Offering referenced above, on December 12, 2023, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with Roger Jeffs, the Chief Executive Officer of the Company, in connection with the private sale of 139,665 unregistered shares (the “Private Shares” and together with the Public Shares, the “Shares”) of the Company’s Common Stock, in a private placement at a purchase price of $7.16 per share for an aggregate investment amount of approximately $1 million (the “Private Placement”).","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-125203","anchor_url":"https://secwatch.observer/filing/0001104659-23-125203#claim-ab4b7e78f905ffd575ac9e83a3c29cd433d9e24e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923125203/0001104659-23-125203-index.htm"},{"fact_type":"material_agreement","fact_key":"86c64f3e28512e3d1a6ffc616bd8d46e3d8c4c65","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2023-12-12T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"BofA Securities, Inc.","effective_date":"2023-12-12","item_codes_triggered":["1.01"],"value_text":"Sale of 3,491,620 shares of common stock at $7.16 per share, gross proceeds approximately $25 millio"},"claim":"Liquidia Corp entered into Underwriting Agreement with BofA Securities, Inc. valued at Sale of 3,491,620 shares of common stock at $7.16 per share, gross proceeds approximately $25 millio (effective 2023-12-12).","evidence_excerpt":"On December 12, 2023, Liquidia Corporation, a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with BofA Securities, Inc. (“ Representative ”), as representative of the several underwriters named therein (collectively, the “Underwriters”), in connection with a sale of 3,491,620 shares (the “Public Shares”) of the Company’s common stock, par value $0.001 per share ( the “Common Stock), pursuant to a registration statement on Form S-3 (File No. 333-251394), filed with the United States Securities and Exchange Commission (the “SEC”) on December 16, 2020, and which was declared effective by the SEC on December 23, 2020, and the prospectus contained therein, as may be supplemented by a prospectus supplement (the “Prospectus Supplement ”) to be filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act ”), in an underwritten registered public offering (the “Offering”) at an offering p","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-23-125203","anchor_url":"https://secwatch.observer/filing/0001104659-23-125203#claim-86c64f3e28512e3d1a6ffc616bd8d46e3d8c4c65","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923125203/0001104659-23-125203-index.htm"},{"fact_type":"earnings_release","fact_key":"1310d8cc950206c1e62f97e7dbf5cdfad2fbbf2f","cik":1819576,"ticker":"LQDA","company_name":"Liquidia Corp","filed_at":"2023-11-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the third quarter ended September 30, 2023","report_date":"2023-11-07","result_type":"reported_results","revenue_text":"$3.7 million"},"claim":"Liquidia Corp reported the third quarter ended September 30, 2023 results: revenue $3.7 million.","evidence_excerpt":"for PAH and PH-ILD. Third\nQuarter 2023 Financial Results Cash totaled $76.2 million as of September 30, 2023, compared to $93.3 million as of December 31, 2022. Revenue was $3.7 million for the three months ended September 30, 2023, compared to $3.2 million for the three months ended September 30,\n2022. Revenue related primarily to the promotion agreement","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-23-114983","anchor_url":"https://secwatch.observer/filing/0001104659-23-114983#claim-1310d8cc950206c1e62f97e7dbf5cdfad2fbbf2f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1819576/000110465923114983/0001104659-23-114983-index.htm"}]}